Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagnostic criteria are still based on nonspecific signs and symptoms and because common severity criteria correlate poorly with adverse maternal and fetal outcomes. The discovery of the role of angiogenesis-related factors - soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) - in the underlying pathophysiology of PD has marked an important step for improving its early diagnosis and prognosis assessment before gestational week 34. Nowadays, an sFlt-1/PlGF ratio cutoff level of ≤38 is widely accepted for ruling out PE in patients with suspicion of the disease, and its use is cost-effective. However, the evidence is more limited regarding the management and prognosis of women with an abnormally high sFlt-1/PlGF ratio. This review summarizes the current evidence of the clinical application of the sFlt-1/PlGF ratio for the diagnosis and prognosis assessment of PE and points out the next challenges for these biomarkers, including their role as target for the development and monitoring of new therapies.

Keywords:
Placental dysfunction, Preeclampsia, Angiogenesis, sFlt-1/PlGF ratio
1.
Friedman AM, Cleary KL: Prediction and prevention of ischemic placental disease. Semin Perinatol 2014;38:177-182.
2.
Burton GJ, Woods AW, Jauniaux E, Kingdom JC: Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009;30:473-482.
3.
Roberts JM: Pathophysiology of ischemic placental disease. Semin Perinatol 2014;38:139-145.
4.
Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H: The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012;58:837-845.
5.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
6.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
7.
Weiler J, Tong S, Palmer KR: Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One 2011;6:e26937.
8.
Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ: Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108:338-344.
9.
Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A: Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol 2014;43:525-532.
10.
Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L, Hassan SS: Plasma concentrations of angiogenic/antiangiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014;27:132-144.
11.
Redman CW, Sargent IL, Staff AC: IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta 2014;35(suppl):S20-S25.
12.
Roberts JM, Catov JM: Preeclampsia more than 1 disease: or is it? Hypertension 2008;51:989-990.
13.
Herraiz I, Dröge LA, Gómez-Montes E, Henrich W, Galindo A, Verlohren S: Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol 2014;124:265-273.
14.
Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, Thadhani R, Karumanchi SA: Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189-201.
15.
Redman CW, Staff AC: Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 2015;213(4 suppl):S9.e1, S9-S11.
16.
Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, Kyle P, Lee SK, Moore MP, Moutquin JM, Smith GN, Walker JJ, Walley KR, Russell JA, von Dadelszen P: Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447-462.
17.
American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-1131.
18.
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC: A study protocol for the prospective validation study: Screening programme for pre-eclampsia (SPREE). Ultrasound Obstet Gynecol 2017, Epub ahead of print.
19.
Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O'Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A: Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(suppl 1):1-203.
20.
Shennan AH, Redman C, Cooper C, Milne F: Are most maternal deaths from pre-eclampsia avoidable? Lancet 2012;379:1686-1687.
21.
Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
22.
Zhang J, Klebanoff MA, Roberts JM: Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001;97:261-267.
23.
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S: Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13-22.
24.
Verlohren S, Llurba E, Chantraine F, Vatish M, Staff A, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Schoedl M, Dilba P, Hund M, Zeisler H: The sFlt-1/PlGF ratio can rule out preeclampsia for up to four weeks in women with suspected preeclampsia (abstract). Pregnancy Hypertens 2016;6:140-141.
25.
Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH: Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-2131.
26.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H: New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346-352.
27.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H: The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e1-e8.
28.
Haddad B, Sibai BM: Expectant management in pregnancies with severe pre-eclampsia. Semin Perinatol 2009;33:143-151.
29.
von Dadelszen P, Payne B, Li J: Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011;377:219-227.
30.
Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, Verlohren S: The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 2014;42:61-68.
31.
Schaarschmidt W, Stepan H: The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41:511-516.
32.
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dinkel C, Schoedl M, Dilba P, Hund M, Verlohren S: Soluble fms-Like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. Obstet Gynecol 2016;128:261-269.
33.
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-919.
34.
Broekhuijsen K, van Baaren G, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, Oudijk MA, Bloemenkamp KWM, Scheepers HCS, Bremer HA, Rijnders RJP, van Loon AJ, Perquin DAM, Sporken JMJ, Papatsonis DNM, van Huizen ME, Vredevoogd CB, Brons JTJ, Kaplan M, van Kaam AH, Groen H, Porath MM, van den Berg PP, Mol BWJ, Franssen MTM, Langenveld J: Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 2015;385:2492-2501.
35.
Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374:979-988.
36.
Llurba E, Marsal G, Sanchez O, Dominguez C, Alijotas-Reig J, Carreras E, Cabero L: Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 2012;40:367-369.
37.
Goa S, Mimura K, Kakigano A, Tomimatsu T, Kinugasa-Taniguchi Y, Endo M, Kanagawa T, Kimura T: Normalisation of angiogenic imbalance after intra-uterine transfusion for mirror syndrome caused by parvovirus B19. Fetal Diagn Ther 2013;34:176-179.
38.
Hund M, Verhagen-Kamerbeek W, Reim M, Messinger D, van der Does R, Stepan H: Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia - the PreOS study protocol. Hypertens Pregnancy 2015;34:102-115.
39.
Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-950.
40.
Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T: Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 2016;27:903-913.
41.
Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, Hastie R, Onda K, Kaitu'u-Lino TJ: Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 2015;66:687-697.
42.
Costantine MM, Cleary K: Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013;121:349-353.
43.
Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, Vatish M, Wertaschnigg D, Galindo A: Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241-246.
44.
National Institute for Health and Care Excellence guideline DG 23 (2016): PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). Available at https://www.nice.org.uk/guidance/dg23/chapter/1-recommendations (accessed January 2017).
45.
Stepan H, Kuse-Föhl S, Klockenbusch W, Rath W, Schauf B, Walther T, Schlembach D: Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). Geburtshilfe Frauenheilkd 2015;75:900-914.
46.
Di Martino D, Cetin I, Frusca T, Ferrazzi E, Fuse F, Gervasi MT, Plebani M, Todros T: Italian Advisory Board: sFlt-1/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management. Eur J Obstet Gynecol Reprod Biol 2016;206:70-73.
47.
Hadker N, Garg S, Costanzo C, Miller JD, Foster T, van der Helm W, Creeden J: Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ 2010;13:728-737.
48.
Schnettler W, Dukhovny D, Wenger J, Salahuddin S, Ralston RJ, Rana S: Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG 2013;120:1224-1232.
49.
Vatish M, Strunz-McKendry T, Hund M, Allegranza D, Wolf C, Smare C: sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK. Ultrasound Obstet Gynecol 2016;48:765-771.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.